Guanine

Guanine

SCHEMBL641789

Nc1nc2nc[nH]c2c(=O)[nH]1.c1cncnc1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PNP P00491 4/20 0.79
GRIA1 P42261 1/20 0.51
GRIA2 P42262 1/20 0.51
GRIA3 P42263 1/20 0.51
GRIA4 P48058 1/20 0.51
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
GDA Q9Y2T3 1/20 0.43
FGFR1 P11362 1/20 0.42
FGFR2 P21802 1/20 0.42
DPP4 P27487 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL27753678 0.91 PNP (0.79) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL28295810 0.91 PNP (0.65) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL28068968 0.90 PNP (0.63) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL27782399 0.90 PNP (0.63) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL28171868 0.89 PNP (0.93) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL986801 0.89 PNP (1.00) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL1264884 0.89 PNP (1.00) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL5260 0.89 PNP (1.00) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL16552675 0.89 PNP (0.62) PNPGRIA1GRIA2GRIA3GRIA4
Guanine SCHEMBL7211609 0.88 PNP (0.60) PNPGRIA1GRIA2GRIA3GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105658797-A Compositions and methods for modulating RNA RANA医疗有限公司 2016-06-08 CN claimed
US-9186399-B2 Immune stimulatory oligonucleotide analogs containing modified sugar moieties AdiutTide Pharmaceuticals GmbH (DE) 2015-11-17 US claimed
EP-2197488-B1 IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES ADIUTIDE PHARMACEUTICALS GMBH (DE) 2014-05-07 EP claimed
US-20110098456-A1 IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES ADIUTIDE PHARMACEUTICALS GMBH (DE) 2011-04-28 US claimed
JP-2011500014-A 2011-01-06 JP claimed
CN-101820908-A Immunostimulatory oligonucleotide analogs comprising modified sugar moieties COLEY PHARM GMBH 2010-09-01 CN claimed
EP-2197488-A1 IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES Coley Pharmaceuticals GmbH (DE) 2010-06-23 EP claimed
WO-2009047610-A1 IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES COLEY PHARMACEUTICAL GMBH (DE) 2009-04-16 WO claimed
CN-100379879-C Method for measuring DNA polymerization and applications of method CAVIDI TECH AB (SE) 2008-04-09 CN claimed
CN-101027389-A Method for preparing L-arginine, L-ornithine or L-citrulline KYOWA HAKKO KOGYO KK (JP) 2007-08-29 CN claimed
EP-3724225-A1 ANTI-CCT5 BINDING MOLECULES AND METHODS OF USE THEREOF Juno Therapeutics, Inc. (US) 2020-10-21 EP disclosed
CN-110418647-A The nucleic acid modifying enzyme and its application method of RNA guidance UNIV CALIFORNIA 2019-11-05 CN disclosed
CN-110079588-A For the method for nucleic acid amplification, composition, system, instrument and kit 生命技术公司 2019-08-02 CN disclosed
CN-110055247-A SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE 株式会社博纳克 2019-07-26 CN disclosed
CN-110023494-A RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF 加利福尼亚大学董事会 2019-07-16 CN disclosed
US-20060211644-A1 Immunostimulatory oligonucleotides COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-09-21 US disclosed
WO-2006091915-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-31 WO disclosed
US-20060019923-A1 Methods and compositions for inducing innate immune responses COLEY PHARMACEUTICAL GROUP, LTD. (CA) 2006-01-26 US disclosed
CN-1489477-A Conjugates of glycosylated/galactosylated peptides, bifunctional linkers, and nucleotide monomers/polymers, and related compositions and methods of use 2004-04-14 CN disclosed
CN-1425023-A Transgenic mice containing TRP gene disruptions DELTAGEN INC (US) 2003-06-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098456-A1 IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES NT5C2, TLR3, TLR9 PNP 36/4885GRIA1 1897/4885GRIA2 2221/4885
US-20060019923-A1 Methods and compositions for inducing innate immune responses TLR3, MYD88, TLR1 PNP 3194/4885GRIA1 1662/4885GRIA2 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.